Your browser doesn't support javascript.
Comparison of Different Antiviral Regimens in the Treatment of Patients with Severe COVID-19: A Retrospective Cohort.
Mahfouz, Mohammad E M; Alharthi, Afrah A; Alsalmi, Nada M; Alnemari, Ahad A; Alwagdani, Amjad A; Alghamdi, Reem K; Almakki, Razan A; Al Yami, Mubarak R; Alghamdi, Ahmed N; Osman, Afaf S; Abdel-Moneim, Ahmed S; Kadry, Dalia Y.
  • Mahfouz MEM; Department of Surgery, College of Medicine, Taif University, Taif 21944, Saudi Arabia.
  • Alharthi AA; College of Medicine (Graduate Students), Taif University, Taif 21944, Saudi Arabia.
  • Alsalmi NM; College of Medicine (Graduate Students), Taif University, Taif 21944, Saudi Arabia.
  • Alnemari AA; College of Medicine (Graduate Students), Taif University, Taif 21944, Saudi Arabia.
  • Alwagdani AA; College of Medicine (Graduate Students), Taif University, Taif 21944, Saudi Arabia.
  • Alghamdi RK; College of Medicine (Graduate Students), Taif University, Taif 21944, Saudi Arabia.
  • Almakki RA; College of Medicine (Graduate Students), Taif University, Taif 21944, Saudi Arabia.
  • Al Yami MR; King Faisal Medical Center (KFMC) Taif 26514, Saudi Arabia.
  • Alghamdi AN; Department of Microbiology, College of Medicine, Taif University, Taif 21944, Saudi Arabia.
  • Osman AS; Medical Pharmacology Department, Faculty of Medicine, Cairo University, Cairo 11562, Egypt.
  • Abdel-Moneim AS; Department of Microbiology, College of Medicine, Taif University, Taif 21944, Saudi Arabia.
  • Kadry DY; Department of Microbiology, National Cancer Institute, Cairo University, Cairo 11796, Egypt.
Medicina (Kaunas) ; 59(2)2023 Jan 29.
Article in English | MEDLINE | ID: covidwho-2216597
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes respiratory disorders, with disease severity ranging from asymptomatic to critical manifestations. The current retrospective study compared the efficacies of different antiviral regimens used in patients suffering from severe COVID-19 disease from 19 January 2020 to December 2021 in a single center in Saudi Arabia. In total, 188 patients were enrolled in the current study, including 158 patients treated with different antiviral regimens, and 30 who did not receive any antiviral treatment. Different antiviral regimens, including favipiravir, remdesivir, oseltamivir, favipiravir/remdesivir, and favipiravir/oseltamivir were adopted. The effects of using different antivirals and antibiotics on the survival rate were evaluated, as well as the presence of comorbidities. Among all severely affected patients, 39/188 (20.7%) survived. Both age and comorbidities, including diabetes and hypertension, were significantly correlated with high case fatality following SARS-CoV-2 infection. Remdesivir alone and the combination of favipiravir and remdesivir increased the survival rate. Surprisingly, both imipenem and linezolid helped in the deterioration of disease outcome in the patients. A negative correlation was detected between increased mortality and the use of favipiravir and the use of either imipenem or linezolid. Among the compared antiviral regimens used in the treatment of severe COVID-19, remdesivir was found to be an effective antiviral that reduces COVID-19 case fatality. Antibiotic treatment using imipenem and/or linezolid should be carefully re-evaluated.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal subject: Medicine Year: 2023 Document Type: Article Affiliation country: Medicina59020260

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal subject: Medicine Year: 2023 Document Type: Article Affiliation country: Medicina59020260